Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis

No Abstract.Journal of Endocrinology, Metabolism and Diabetes of South Africa Vol. 10(2) 2005: 51-5

Lipohypertrophy - a complication of insulin injections

No Abstract.Journal of the Society for Endocrinology, Metabolism and Diabetes of South Africa Vol. 11 (2) 2002: pp. 64-6

Chapter 10: Glucose control: insulin therapy

The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee.Chapter 10. Glucose control: insulin therapy in 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. JEMDSA 2017; 21(1 (Supplement 1): S49-50

Chapter 11: The approach to achieving glycaemic control

The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee.Chapter 11. The approach to achieving glycaemic control in 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. JEMDSA 2017; 21(1)(Supplement 1): S51-5

Serum ferritin transferrin saturation were independently associated with pre-diabetes among U.S. adults

Oral Presentations - Endocrinology and Metabolism: no. C075OBJECTIVE: Increased serum ferritin concentrations have been reported to be associated with insulin resistance and an increased risk of developing Type 2 diabetes. However, the exact mechanism leading to this association is not well understood. Previous reports have attributed this association to subclinical iron overload. In our study, we examined the correlation of three markers of iron homeostasis with glucose metabolism and the risk of pre-diabetes among U.S. adults without iron deficiency and chronic kidney disease …postprin

Editorial: Advances in Endocrinology: Stem Cells and Growth Factors

Stem Cells investigation in Endocrinology: leading stem cell scientists and developmental endocrinologists, critically review both cutting-edge approaches to stem cell biology and the application of stem cells and their secretome to translational/precision medicine, endocrine diseases, including diabetes, tissue/organ repairs, energy metabolism, and metabolic disorders

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes

Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk reduction. Objective To determine whether liraglutide at clinical dosing augments myocardial glucose uptake alone or in combination with insulin compared to insulin alone in metformin-treated Type 2 diabetes mellitus. Design Comparison of myocardial fuel utilization after 3 months of treatment with insulin detemir, liraglutide, or combination detemir+liraglutide. Setting Academic hospital Participants Type 2 diabetes treated with metformin plus oral agents or basal insulin. Interventions Insulin detemir, liraglutide, or combination added to background metformin Main Outcome Measures Myocardial blood flow, fuel selection and rates of fuel utilization evaluated using positron emission tomography, powered to demonstrate large effects. Results We observed greater myocardial blood flow in the insulin-treated groups (median[25th, 75th percentile]: detemir 0.64[0.50, 0.69], liraglutide 0.52[0.46, 0.58] and detemir+liraglutide 0.75[0.55, 0.77] mL/g/min, p=0.035 comparing 3 groups and p=0.01 comparing detemir groups to liraglutide alone). There were no evident differences between groups in myocardial glucose uptake (detemir 0.040[0.013, 0.049], liraglutide 0.055[0.019, 0.105], detemir+liraglutide 0.037[0.009, 0.046] µmol/g/min, p=0.68 comparing 3 groups). Similarly there were no treatment group differences in measures of myocardial fatty acid uptake or handling, and no differences in total oxidation rate. Conclusions These observations argue against large effects of GLP-1 agonists on myocardial fuel metabolism as mediators of beneficial treatment effects on myocardial function and ischemia protection

Introduction

A Symposium on Diabetes was presented at the Medical College of Virginia on September 23, 1976, sponsored jointly by the Division of Endocrinology and Metabolism of the Department of Medicine, and by the Department of Continuing Education. The symposium was also sponsored in part by a grant-in-aid for continuing medical education from the Upjohn Company